Clinical trials: Immune Suppression
Myositis Associated Interstitial Lund Disease (MA-ILD)
Myositis Interstitial Lung Disease Nintedanib Trial
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).
- Trial name
- MINT (NCT05799755)
- Testing
- Nintedanib, Standard of Care
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Rohit Aggarwal, MD
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
This phase I trial studies the side effects and best dose of iodine I 131monoclonal antibody BC8 when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, and donor bone marrow transplant, and to…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, CD45-Positive Neoplastic Cells Present
- Trial name
- NCT00589316
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Fred Hutchinson Cancer Center
Kidney Transplant Failure and Rejection
Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients
The primary objective is to compare the effect of treatment with an immediate-release tacrolimus to an extended-release tacrolimus (i.e., Envarsus® XR) immunosuppressive regimen on cognitive and motor function in kidney…
- Trial name
- NCT03437577
- Testing
- immediate-release tacrolimus, extended release tacrolimus
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Minnesota
Living Donor Liver Transplantation
DCreg in Living Donor Liver Transplantation
Phase I/II, single center, prospective, open-label, non-controlled, non-randomized, interventional, cohort study in which low risk living donor liver transplant (LDLT) recipients will receive a single infusion of donor-derived…
- Trial name
- NCT03164265
- Testing
- Regulatory Donor-Derived Dendritic Cell infusion
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Angus W. Thomson PhD DSc
Aplastic Anemia, Pure Red Cell Aplasia
A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
Participants in this study are suffering from rare and serious blood disorders. In aplastic anemia, the bone marrow stops producing red blood cells, platelets, and white blood cells.
- Conditions
- Aplastic Anemia, Pure Red Cell Aplasia, Diamond Blackfan Anemia
- Trial name
- NCT00001962
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Wegener's Granulomatosis
Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Wegener's granulomatosis is a primary systemic vasculitis characterized by granulomatous and necrotizing inflammation predominantly affecting the respiratory tract and the kidneys.
- Trial name
- NCT00530075
- Testing
- Gusperimus
- Where
- 7 sites in Czechia, Denmark and 4 more
- Volunteers
- 45 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Liver Transplant, Liver Transplantation
Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
The primary aim of this study is to determine whether a peripheral blood or graft lymphocyte phenotype of immune senescence or exhaustion is different between operationally tolerant and non-tolerant liver allograft recipients.
- Trial name
- OPTIMAL (NCT02533180)
- Testing
- Immunosuppression withdrawal
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunosuppression, COVID-19
Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations
To determine whether providing a recombinant booster COVID-19 vaccine improves sustained humoral and cell-mediated immunogenicity against SARS-CoV-2 in immunosuppressed patients with Inflammatory Bowel Disease (IBD) and/or solid…
- Trial name
- NCT06027229
- Testing
- NVX-CoV2372
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Wisconsin, Madison
Immunosuppression
Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status
Tacrolimus (Prograf) is a medication that is commonly used in patients who receive a kidney transplant. It is considered to be one of the most important medications that prevent rejection of the transplant kidney by suppressing…
- Trial name
- TIMELY (NCT00731874)
- Testing
- Tacrolimus
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Weill Medical College of Cornell University
End Stage Renal Disease, Rejection of Renal Transplant
Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
The overall aim of the study is to prospectively investigate the impact of two maintenance calcineurin inhibitor immunosuppressive regimens: once-daily extended release tacrolimus and twice-daily tacrolimus on subpopulations of T…
- Trial name
- NCT03289650
- Testing
- Tacrolimus, Tacrolimus Extended Release Oral Tablet [Envarsus]
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Lorenzo Gallon
Other Complication of Kidney Transplant, Renal Transplant Rejection
Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients
Steroids are one of the pillars of immunosuppression for kidney transplant patients but their use is associated with a high rate of complications.
- Trial name
- NCT02284464
- Testing
- Prednisone withdrawal, Prednisone continuation
- Where
- 5 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid
Treatment and Natural History Study of Lymphomatoid Granulomatosis
This study will evaluate the response and long-term effects of alpha-interferon in patients with lymphomatoid granulomatosis (LYG).
- Conditions
- Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00001379
- Testing
- Interferon, Rituxan and EPOCH, Tumor biopsy
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Failure
Everolimus Monotherapy as Immunosuppression After Liver Transplant
Tacrolimus is the standard immunosuppressive drug used to prevent organ rejection post liver transplant. One side effect of Tacrolimus is nephrotoxicity. Everolimus does not have the nephrotoxicity side effects of Tacrolimus.
- Trial name
- NCT04063865
- Testing
- Tacrolimus, Everolimus
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Indiana University
Kidney Transplant Recipients, Liver Transplant Recipients
COVID Protection After Transplant-Immunosuppression Reduction
This study will enroll individuals who have: Completed primary series of mRNA COVID-19 vaccine, and An antibody response ≤ 2500 U/mL measured at least 30 days after the last dose of vaccine.
- Trial name
- CPAT-ISR (NCT05077254)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen
- Where
- 15 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Age-Related Macular Degeneration, Choroidal Neovascularization
Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
This study examined whether the anti-inflammatory medicines infliximab, sirolimus or daclizumab, when given with a participant's current therapies, would prevent the growth of new blood vessels in the eye in participants with…
- Trial name
- AMDB1 (NCT00304954)
- Testing
- Intravenous Daclizumab, Intravenous Infliximab, Observation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Eye Institute (NEI)
HIV Infections
Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1
This was a prospective, non-interventional, single-arm, multi-center study aimed at gathering real-world data on JULUCA use in routine clinical care in Germany, to supplement clinical trial data to further improve/optimize care…
- Trial name
- JUNGLE (NCT03518060)
- Testing
- JULUCA
- Where
- 23 sites in Germany
- Volunteers
- 209 people
- Sponsor
- ViiV Healthcare
HIV Infections
FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment
For people with HIV who are currently taking specific medications (including Sustiva (efavirenz)) and have no detectable viral load, this study tracks how patients do if they take their medications for five days of the week…
- Trial name
- NCT00414635
- Testing
- Intermitent Dosing
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Community Research Initiative of New England
Immunosuppression, Kidney Transplantation
HLA-Identical Sibling Renal Transplant Tolerance
The purpose of this study is to attempt to eliminate the necessity of immunosuppressive therapy for HLA-identical sibling Kidney Transplants, examine cellular chimerism of donor hematopoietic stem cell (DHSC) lineages for pairs…
- Conditions
- Immunosuppression, Kidney Transplantation, Graft Rejection
- Trial name
- NCT00619528
- Testing
- Infusion of Donor Hematopoietic Stem Cells and Campath-1H
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Asthma
Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects
This is a randomized, placebo-controlled, 2-period crossover, escalating repeat dose study, aiming to investigate whether higher potency of different inhaled corticosteroid confers an improvement in the topical efficacy to…
- Trial name
- NCT02991859
- Testing
- Fluticasone furoate (FF) Dry Powder Inhaler, Fluticasone propionate (FP) Dry Powder Inhaler, Budesonide (BUD) Turbuhaler
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Anterior Uveitis, Arthritis, Juvenile Idiopathic
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
This study will examine the safety and effectiveness of a monoclonal antibody called humanized anti-Tac (HAT, also called daclizumab) to treat children and adolescents with uveitis (chronic inflammatory eye disease) associated…
- Conditions
- Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
- Trial name
- NCT00130637
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)